Exhale

The official blog of the Lung Institute.

Lung Institute Applauds Texas Medical Freedom Act

19 Jun 2017
| Under Press | Posted by | 2 Comments
Lung Institute Applauds Texas Medical Freedom Act

DALLAS, Texas, June 14, 2017 – Government officials in Texas have passed a bill that supports cellular therapys, placing Texas at the forefront as the first state to explicitly provide legal validation to cellular therapys for terminal illnesses. This new law falls under the category of the “Right to Try” initiative.

The Lung Institute, the largest cellular therapy center in the U.S. for chronic lung diseases, applauds this legislation, particularly in light of the great success they’ve already seen at their Dallas clinic, which opened in April of 2016.

“We are very excited about the support that we’re seeing in Texas,” said Jack Coleman, M.D., medical director for the Lung Institute. “Cellular technologies are reshaping how medicine is practiced in the U.S., yet our traditional way of introducing a medication, instrument or procedure has been found to be too slow, too expensive, too cumbersome and frequently, not applicable to the situation. We’re glad to see that lawmakers appear to be recognizing this as a significant threat to population health.”

In passing this bill, Texas lawmakers seem to support this sentiment. The original proposed bill states, among other things, that “patients who are battling a severe chronic disease that is debilitating or causes severe pain do not have the luxury of waiting until an investigational drug, biological product, or device receives final approval from the United States Food and Drug Administration.”

The law not only provides patients and their primary care doctors with support in making informed decisions about treatment options for chronic debilitating conditions, but also lays the groundwork for regulations that ensure patient safety and treatment efficacy.

Lung Institute’s clinic has worked closely with an IRB since first opening, and collects all patient data and outcomes. With any new procedure, collecting outcomes is imperative in measuring treatment effectiveness, and Texas’ requirement for IRB oversight ensures that cellular therapy centers provide data and have patients’ best interests in mind.

One Lung Institute patient from Texas, Herbert K., decided to visit the Lung Institute for treatment when his lung capacity was as low as 15 percent due to COPD. Within two months of treatment, a pulmonary function test revealed his lung capacity had improved to 31 percent. COPD is a progressive disease, meaning it will only get worse with time, and there is currently no cure. COPD patients face limited options, and laws like the “Right to Try” act in Texas that show support for cellular therapys provide hope for patients with terminal illnesses.

“I just cannot thank the Lung Institute enough for what they’ve given me, in my opinion, is a second opportunity at enjoying my retirement,” said Herbert. “It’s just been a wonderful experience.”

Watch Herbert’s full testimonial video HERE.

About the Lung Institute:

The Lung Institute is the leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date, the organization has treated more than 4,000 patients. The Lung Institute’s in-house outcomes summary shows that 84.5 percent of COPD patients studied saw an improvement in their quality of life. In 2013, the Lung Institute in Tampa, Fla. opened. Now, the Lung Institute operates clinics in Tampa, Fla.; Nashville, Tenn.; Scottsdale, Ariz.; Pittsburgh, Pa, and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 382-8095.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.